The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects

Farhad Dehkhoda, Christine M. M. Lee, Johan Medina and Andrew J. Brooks*

The University of Queensland Diamantina Institute, Translational Research Institute, The University of Queensland, Brisbane, QLD, Australia

The growth hormone receptor (GHR), although most well known for regulating growth, has many other important biological functions including regulating metabolism and controlling physiological processes related to the hepatobiliary, cardiovascular, renal, gastrointestinal, and reproductive systems. In addition, growth hormone signaling is an important regulator of aging and plays a significant role in cancer development. Growth hormone activates the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling pathway, and recent studies have provided a new understanding of the mechanism of JAK2 activation by growth hormone binding to its receptor. JAK2 activation is required for growth hormone-mediated activation of STAT1, STAT3, and STAT5, and the negative regulation of JAK–STAT signaling comprises an important step in the control of this signaling pathway. The GHR also activates the Src family kinase signaling pathway independent of JAK2. This review covers the molecular mechanisms of GHR activation and signal transduction as well as the physiological consequences of growth hormone signaling.

Keywords: growth hormone, growth hormone receptor, Janus kinase 2, Src family kinase, insulin-like growth factor 1, suppressor of cytokine signaling

INTRODUCTION

The growth hormone receptor (GHR) is a member of the class I cytokine receptor family, which includes more than 30 receptors such as the prolactin receptor (PRLR), erythropoietin receptor (EPOR), thrombopoietin receptor (TPOR), granulocyte-macrophage colony-stimulating factor receptor, interleukin-3 receptor, interleukin-6 receptor, and interleukin-7 receptor (1, 2). GHR has been considered the archetypal class I cytokine receptor as it was the first cytokine receptor to be cloned and have its extracellular domain (ECD) crystal structure solved (3). GHR is a 638 amino acid long homodimeric receptor with one cytokine receptor homology domain (CRH), a single-pass transmembrane domain, and cytoplasmic intracellular domain (ICD) (Figure 1). With the exception of GHR, all members of the class I cytokine receptor family contain a WSXWS motif in the ECD. The WSXWS motif is important for expression and stability of the receptor and comprises a consensus sequence for χ-mannosylation. For the IL-21R, the WSXWS has been shown to be mannosylated at the first tryptophan where the sugar chain appears to form structurally important interactions that bridge the two fibronectin domains (4, 5). GHR has in place of the WSXWS a similar sequence of YGeFS that has an analogous function in expression and stability.
of the receptor (1). Cytokine receptors lack an intrinsic protein tyrosine kinase (PTK) activity and therefore rely on binding non-receptor PTKs for their signal transduction. Within the ICD of all class I cytokine receptors is a proline-rich Box1 motif that is located a short distance from the cell membrane. A less conserved Box2 sequence consisting of acidic and aromatic residues is located a short distance C-terminal of the Box1 (1). The Box1 motif acts as a binding site for a cognate Janus kinase (JAK) of which there are four family members, JAK1, JAK2, JAK3, and TYK2 that can bind to specific receptors (Table 1). For GHR, the only JAK family member that binds the receptor is JAK2. GH binding to GHR results in activation of JAK2, which subsequently phosphorylates multiple tyrosine residues on the ICD of the receptor (Figure 2) (6, 7). This provides a scaffold for binding of STAT5a and STAT5b, which are subsequently phosphorylated by JAK2 upon receptor docking (Figure 3) (8). GHR also activates STAT1 and STAT3 via JAK2; however, these STATs do not appear to require binding to the phosphorylated receptor. Other signaling pathways such as the Ras/extracellular signal-regulated kinase (ERK) and PI 3-kinase/Akt are also activated by GHR (7, 9). The consequence of these GH-mediated cellular signaling pathways in a diverse range of cell types is responsible for the large range of physiological processes regulated by GH.

**GHR STRUCTURE AND ACTIVATION MECHANISM**

The crystal structure of GH bound to the GHR ECD showed that one GH molecule bound two GHR molecules (3). Biophysical studies demonstrated that GH binds initially to a single receptor through its “site 1” motif and then subsequently binds to the second receptor via its “site 2” interactions (41, 42). The major energy contributor residues of the hormone–receptor complex were identified as residues in the receptor hydrophobic patch, where tryptophan104 and tryptophan169 contributed significantly to site 1 interactions. In addition, tryptophan104 plays a key role in the weaker site 2 interaction (43, 44). These studies suggested GH binding causes receptor dimerization, which induces intracellular signal transduction. This dimerization-induced activation model was supported by a study using a hybrid receptor of the GHR ECD fused to the base of the CRH domain of granulocyte colony-stimulating factor receptor (G-CSFR) with the remaining fibronectin type III homology domains (FNIII), transmembrane, and ICD. Monoclonal antibodies to the GHR ECD activated the hybrid receptor whereas monovalent fragments did not; however, the additional FNIII domains may have influenced these data (45). In addition, of eight antibodies that were effective agonists for the GHR/G-CSFR hybrid, only one antibody acted as an agonist with weak activity on full-length GHR, suggesting that receptor dimerization alone is not sufficient for activation (46). Later studies using site 2-modified GH antagonists, which would be predicted to bind only GHR monomer, appeared to bind GHR dimers expressed on cell membranes, thus demonstrating the existence of GHR dimers before GH binding (47). Subsequent studies confirmed that GHR dimers exist on the cell surface, and that dimers form in the endoplasmic reticulum. It was also shown that the extracellular region is not required for maintaining receptor dimers, although the lower FNIII domain may define receptor-dimer specificity (48–52). Data supporting the GHR preformed dimer
TABLE 1 | Class I cytokine receptors and their Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling partners.

| Receptor group     | Receptor            | Partner JAK/s      | Activated STAT/s | Reference |
|--------------------|---------------------|--------------------|------------------|-----------|
| Homomeric receptors| Growth hormone receptor | JAK2              | STAT1, STAT3, and STAT5 | (10, 11) |
|                    | EPOR                 | JAK2              | STAT1, STAT3, and STAT5 | (12–14) |
|                    | Prolactin receptor   | JAK2              | STAT1, STAT3, and STAT5 | (15–17) |
|                    | Thrombopoietin receptor | JAK2 and TYK2   | STAT1, STAT3, and STAT5 | (16–20) |
|                    | G-CSFR               | JAK1 and JAK2     | STAT1, STAT3, and STAT5 | (21, 22) |
|                    | OBR                  | JAK2              | STAT3, STAT5, and STAT6 | (23, 24) |
| βc Heteromeric receptors| IL-3Rα             | JAK2              | STAT5 and STAT6  | (25–27) |
|                    | IL-5Rα               | JAK2              | STAT1, STAT3, and STAT5 | (28, 29) |
|                    | GMRFα                | JAK2              | STAT1, STAT3, and STAT5 | (30, 31) |
| GP130 heteromeric   | IL-6Rα              | JAK1, JAK2, and TYK2 | STAT1 and STAT3 | (32, 33) |
|                    | IL-11Rα             | JAK1, JAK2, and TYK2 | STAT1 and STAT3 | (34, 35) |
|                    | LIFR                 | JAK1 and JAK2     | STAT1 and STAT3  | (36)      |
| γc Heteromeric receptors| IL-2Rα              | JAK1 and JAK3     | STAT3 and STAT5  | (37)      |
|                    | IL-4Rα              | JAK1 and JAK3     | STAT6            | (38, 39) |
|                    | IL-7Rα              | JAK1 and JAK3     | STAT3 and STAT5  | (40)      |

Example receptors shown for each receptor group.

FIGURE 2 | Activation of the growth hormone receptor (GHR) by growth hormone. In the inactive homodimeric GHR, (A) the Janus kinase (JAK) 2 kinase domain (KD) is inhibited in trans by interaction with the pseudokinase domain from the JAK2 bound to the opposing receptor within the homodimer. GH binding to the GHR extracellular domain (B) results in conformational changes that cause the transmembrane domains to transition from a parallel interaction to a left-handed crossover interaction. These structural changes cause a separation of the intracellular domains to the Box1 and Box2 motifs and the associated JAK2 molecules. The movement of the associated JAK2s dissociates the inhibitory interaction of the pseudokinase from the KD and brings the two JAK2 KDs in close proximity resulting in trans phosphorylation and activation.

conclusion were performed independently by more than one group using multiple techniques including co-immunoprecipitation, FRET, BRET, and fluorescence anisotropy (48–51). By analyzing the FRET efficiency with FRET reporters placed at the C-termini of full-length GHR and C-terminal truncations, it was found, in general, that the dimeric-GHR ICDs are positioned at a greater distance apart, the further they are from the transmembrane domain (50). This has been illustrated clearly for the closely related receptor PRLR where a recent full-length structure has been produced, which includes a molecular model of the ICD (53). Crystallographic studies comparing the unliganded ECD of GHR to the ligand-bound form showed no major change in overall structure; however, a 7–9° of rotation between upper and lower
FNIII-type domains of the CRH module was observed, which was small compared with the ligand-induced conformation change shown for the ECD of RTKs (50). It was also evident that ligand binding did not change FRET efficiency of GH receptors with N-terminal reporters confirming lack of major conformational change in the ECDs upon GH binding (50).
JANUS KINASE 2

Most members of the JAK family are widely expressed in many cell types, except JAK3 whose expression is restricted to cells of the hematopoietic lineage (54). While JAK1 and JAK2 are involved in diverse physiological actions such as hematopoiesis, immunity, development, and growth (1, 55, 56), JAK3 and Tyk2 are predominantly involved in homeostasis of immune system (57, 58).

Janus kinases are relatively large proteins ranging from 120 to 140 KD (~1,150 amino acids) (59). The N-terminal half of these proteins comprises N-terminal band 4.1, ezrin, radixin, moesin (FERM) domain followed by Src homology 2 (SH2) domain, which were primarily defined as Janus homology (JH) domains 3–7 (60). These domains play the major role in binding of JAKs to the cytoplasmic tails of their cognate cytokine receptors (61–63). The first evidence demonstrating the role of the N-terminus of JAK2 in receptor interactions was shown using JAK2 mutants, lacking the 239 N-terminal residues that rendered the JAK2 mutant incapable of binding GHR or the membrane proximal region of the common β chain (64, 65). This was further supported by studies showing that the FERM and SH2 domains of JAK1 are essential for association to oncostatin M receptor (OSMR), and that this binding is also required for upregulating surface expression of the OSMR (66, 67). Truncation studies showed that the membrane proximal 61 amino acids of GP130 are sufficient for signal transduction (68), and later it was shown for GHR that the membrane proximal 20 residues (which includes the Box1 motif) of the ICD is sufficient for JAK2 binding, but not sufficient for GH-induced activation of JAK2 (69). Until recently, little was known about the mechanism of receptor–JAK association or how JAKs gain specificity to their cognate receptors. Previous studies have shown that the Box1 motif, although required for JAK binding, is not sufficient to determine the specificity for a particular JAK to associate with its cytokine receptor, and that additional sequences in the receptor play an important role in specificity since JAK1 and JAK2 were shown to have different preferences for GHR, EPOR, and GP130 chimeras (70). The first crystal structure of a JAK bound to residues of a receptor ICD was shown for the FERM–SH2 of TYK2 in complex with the Box2 region of the interferon-α receptor 1 (IFNAR1) (71). This study revealed that the TYK2 FERM–SH2 domains form a clover shaped structure with the SH2 being the forth leaf. The structure showed the FERM domain has a canonical three-lobe structure (F1–F3), and the SH2 has a preserved SH2-like structure despite lacking the highly conserved arginine residue in the phosphotyrosine binding site (71, 72). Interestingly, the SH2 domain coordinates the interactions with IFNAR1 to form the initial connections with the receptor peptide in the C-terminus. Further insights regarding cytokine receptor recognition by JAKs emerged when the crystal structure of JAK1 bound to peptides derived from the IL-10 receptor (IL10RA) and interferon lambda receptor (IFNLR1) was solved (73). These studies showed the Box1 peptide bound to the F2 domain of the FERM while the Box2 peptide was not resolved in the structure. In addition, the binding kinetics of the IFNLR1 Box1 and Box2 showed that Box1 alone has a strong affinity while Box2 alone had no detectable interaction; however, the full Box1–Box2 peptide had a significantly enhanced affinity over Box1 alone, which was proposed to be due to the increased complex stability from the hydrophobic JAK1–Box2 interaction (73). Although neither of these recent structures showed simultaneous interactions between the JAK molecule and both Box1 and Box2 sequences, geometrically both sequences are capable of binding to single JAK protein (73, 74). The crystal structure of the JAK1 FERM–SH2 bound to peptides from IL10RA and IFNLR1 gave a provocative suggestion that the Box1 peptide bound to the FERM domain extends away from the FERM domain to interact with the SH2 domain of the neighboring JAK1 molecule in the crystal lattice. Further studies would be needed to determine if Box1–Box2 sequences can have relevant interactions with two JAKs simultaneously, although it was suggested that this may have been due to a crystal artifact (73). More recently, a crystal structure of the JAK1 FERM–SH2 has been solved with a continuous IFNLR1 Box1–Box2 peptide suggesting that lack full Box1–Box2 peptide in previous structures may have been a crystal artifact (75). Recently, a JAK2 FERM–SH2 structure has been solved; however, this structure is not in complex with any receptor sequence (76).

The C-terminal half of JAK proteins comprises a pseudokinase domain (PKD) followed by a kinase domain (KD), also known as JH2 and JH1, respectively (77). The KD is a typical tyrosine KD and is catalytically active, whereas the adjacent PKD is catalytically inactive and lacks critical residues despite containing a canonical kinase fold (78). The PKD is believed to regulate kinase activity, and its deletion in JAK2 and JAK3 was shown to increase basal activity of the kinase (64, 79–81). Biochemical studies have reported co-immunoprecipitation of JH1 and JH2 of JAK2, and that the pseudokinase acts to inhibit the kinase activity of JAKs (60, 79, 82). Furthermore, recent studies have shown that the PKD of JAK2, unlike the other members of the JAK family, exhibits some catalytic activity via autophosphorylation of two critical residues in the JH2–SH2 linker region, Ser523 and Tyr770, which play an important role in regulating the activity of the KD (82, 83).

MECHANISM OF JAK2 ACTIVATION BY THE GHR

Recent studies have made major strides in elucidating the mechanism of JAK2 activation by GHR (84). Activation of the receptor by GH binding was found to result in an increase in distance between the Box2 motifs of the intracellular receptor domains. This revelation required a new model for JAK2 activation by cytokine binding whereby in the cytokine free receptor, the JAK2 KD is inhibited by a JAK2 PKD in trans (Figure 2). In this model, the KD from one JAK2 molecule bound to a Box1–Box2 motif from one receptor is inhibited by interacting with the PKD from a different JAK2 molecule bound to the opposing receptor within the receptor homodimer. Upon GH binding, there is a structural change in the ECD that changes the receptor transmembrane domain interaction from a parallel form to a left-handed crossover interaction. This structural transition leads to a separation of the ICD, at least to the Box1–Box2 motif,
and dissociates the JAK2 kinase-pseudokinase trans interaction and brings the KDs in proximity allowing trans phosphorylation and activation (1, 51).

Currently, there is no crystal structure available for the JAK2 pseudokinase-kinase to allow observation of the interaction interface between each domain; however, crystal structures for the individual pseudokinase and KDs have been solved (83, 85). The pseudokinase-kinase crystal structure has presently been solved for only one JAK family member, Tyk2 (86). However, the functional Tyk2 interface was only inferred from the crystal structure as there were three significant potential interaction faces identified in the crystal lattice. It could not be determined directly in this structure as to how the pseudokinase and KDs were joined via the interdomain linker as this linker sequence was not resolved in the crystal structure. The potential dimer interface with the largest buried surface area was excluded from detailed analysis as the distance between the termini of each domain was too great to allow each domain to be linked by the interdomain linker peptide (86). However, for a trans-inhibition interaction model, there would be no requirement for each domain to be linked (87), therefore perhaps this interface with the largest buried surface area may have some biological relevance. The interface with the second largest buried surface area in the Tyk2 crystal lattice did place the C- and N-termini in close enough proximity to be linked by the interdomain linker, and this interface was investigated in detail and mutational data did support the biological significance of this interaction surface. There are a number of activating mutations identified for the JAK2 PKD; however, the location of these mutations suggests there may be two interaction interfaces that are involved in regulating the KD (88). For the Tyk2 pseudokinase-kinase crystal structure, a number of JAK-activating mutations were found to lie directly in the proposed domain interface while a second surface of activating mutations was found peripheral to the proposed dimer interface, which includes the position for the JAK2 V617F mutation commonly identified in myeloproliferative neoplasms (89). Interestingly, some JAK2-activating mutations including V617F have been shown to require interaction with a cytokine receptor for their activity, suggesting that these mutations only disrupt inhibition of the pseudokinase when the JAK2 is bound to a receptor (90–93). Intriguingly, this supports previous suggestions that the JAK2 pseudokinase interaction and inhibition of the KD is different between the receptor bound JAK2 and the receptor free JAK2 (90). Molecular modeling of the proposed JAK2 trans-inhibition interaction of the PKD with the KD placed the V617F in proximity to the activation loop of the KD; however, further direct functional and structural data supporting this interaction are currently not available. Although functional data supporting a trans-inhibition model were obtained when constitutive activation of JAK2 was shown with a JAK2 construct where the pseudokinase and KDs were swapped and this construct showed significant cytokine-independent activation only in the presence of wild-type JAK2 (51).

As the GHR ICD is intrinsically disordered with a number of transient secondary structures (94), the C-termini are likely a long distance apart in the inactivated receptor homodimer in a similar manner as illustrated in a recent full structural model of the PRLR (53). Studies using FRET reporters placed at the C-terminus of GHR have shown a transient increase in FRET shortly after GH addition (95). These data likely represent the flexible receptor ICD interacting with the activated JAK2 KDs and being phosphorylated upon multiple tyrosine residues, which subsequently interact with downstream signaling molecules and negative regulators of signaling.

**SIGNAL TRANSDUCERS AND ACTIVATORS OF TRANSCRIPTION (STATs)**

The STATs are important components of the signaling cascades triggered by various cytokines (Table 1). STATs were initially identified as cytokine-induced transcription factors in interferon treated cells (96–98). To date, seven different members of the STAT family have been identified which includes STAT1–4, 5a, 5b, and 6. STAT5a and 5b are encoded by two different genes with high-sequence homology, except for regions in the N- and C-termini (99). In addition, posttranslational modification and proteolytic cleavage have shown to produce additional forms of STAT1 and STAT3 (100). Although the STAT family members are activated via various cytokines, STAT2 and STAT6 are predominantly activated by IFN-α and IL-4, respectively (101). STAT proteins contain six domains, including an N-terminal domain, coiled coil domain, DNA-binding domain, linker domain, SH2 domain, and transactivation domain (98). Each STAT member can be activated by a JAK via phosphorylation of a conserved tyrosine. Activated STATs translocate to the nucleus where they act as transcriptional regulators. Although STAT members including STAT1, 3, and 5 are activated by JAK2 following GH induction (Figure 3), STAT5 is the predominant transcription factor that delivers GH-induced cell proliferation and actions. Activated STAT5 forms homodimers, whereas active STAT1 and STAT3 form both homodimers and STAT1–STAT3 heterodimers (Figure 3) (7, 102, 103).

**GHR-MEDIATED SRC FAMILY KINASE (SFK) SIGNALING**

Src family kinases are non-receptor tyrosine kinases, which comprise nine members, namely, Src, Lck, Hck, Fyn, Blk, Lyn, Fgr, Yes, and York, all of which share a common multidomain topology consisting of consecutive SH3, SH2, and SH1 KDs and a “unique” region located close to the N-terminus, which differentiates each member of the family. The regulation of SFKs is accomplished through mechanisms involving phosphorylation, dephosphorylation, and complex intramolecular interactions that lead to SH3 and SH2 domain displacement (104, 105). Members of the SFKs are essential for the regulation of immune system function and cellular homeostasis (106). Lyn is a unique member of this family because it acts both as a signal amplifier and also as a signal inhibitor while others are known to only play a single role (107). The major functions of Lyn have been attributed to signaling of hematopoietic growth factor receptors and blood cell development as it is expressed in all blood cells except T lymphocytes (108).
Studies have shown that GH can activate SFKs independent of any JAK2 activation (Figure 4) (109). The SFK member Lyn was found to be associated with the membrane proximal 150 residues of the cytoplasmic domain of human GHR, and Lyn was still shown to be activated by GH when using JAK2-deficient γ2A cells. Furthermore, it was reported that a mutant of the GHR Box1, resulting in loss of GHR-mediated JAK2–STAT signaling, still responded to GH stimulation through the activation of SFKs and ERK1/2 (109, 110). These studies suggested that this novel SFK-dependent pathway involves the activation of PLCγ, and a
subsequent release of inositol 1,4,5-triphosphate (IP₃) and diacylglycerol which leads to an increase in the cytoplasmic calcium ion concentration-activating Ras guanine nucleotide exchange factor RasGRP1. This process results in RAS activation and initiation of the ERK1/2 signaling pathway (109). Related studies using growth hormone as a ligand confirmed that this JAK2-independent pathway can activate ERK1/2 through the activation of Ras-like small GTPases, RaLA, and RaLB in NIH-3T3 cells and through the activation of Rap1 and Rap2 (111, 112). Mutations introduced in a loop of the GHR ECD that alters GH-induced conformational changes resulted in impaired ERK1/2 activation but not JAK2 and STAT5 activation. It was shown that GHR interacts with Lyn (an SFK), and that a deficiency in Lyn activation was responsible for the impaired ERK1/2 activation (109). These studies revealed that the extent of JAK2 or SFK signaling is regulated by conformational changes in the ECD. Interestingly, exon 3 deleted GHR, which results in the deletion of 22 amino acids in the ECD exhibits altered ERK signaling, but normal STAT5 and AKT signaling. This study highlighted the physiological importance of altering the signaling strength of these pathways as exon 3-deleted GHR individuals were found to be of higher stature with extended lifespan (113). Studies on closely related cytokine receptors have demonstrated SFK activation for TPOR, EPOR, and PRLR upon ligand binding (114–117). In addition, in a similar manner as shown for GHR, studies illustrate that structural changes in the ECD of EPOR and TPOR alter the extent of JAK2 and SFK signaling independently (118–120). The strength of JAK2 or SFK may also be significantly affected by different expression levels of each kinase in different cell types (109). Evidence also suggests JAK2 may not be the only PTK responsible for the tyrosine phosphorylation of STAT5 following GH stimulation, and that SRC may be taking this role in certain cell types and cytokine receptor systems (115, 121, 122).

NEGATIVE REGULATORS OF JAK–STAT SIGNALING

Negative regulation of cytokine receptor signaling is critical to the correct function of cytokine receptors as dysregulated negative regulation of signaling can lead to disease states. Negative regulators of JAK–STAT signaling can be grouped into three main families, and this includes the suppressor of cytokine signaling (SOCS) protein family, protein tyrosine phosphatase (PTP), and protein inhibitor of activated STAT (PIAS). Apart from these protein families, the SH2-domain containing LNK (SH2B3) adaptor protein has been shown to be an important negative regulator in the JAK–STAT pathway. These negative regulators act in different ways to suppress JAK–STAT signaling. They can target JAKs, STATs, and/or receptors and may also involve other proteins of the proteasomal degradation pathway (123). The various mechanisms that are used by these signal regulators in modulating JAK–STAT signaling will be focused on below.

Suppressor of Cytokine Signaling

The SOCS protein family consists of SOCS1–7 and CIS. SOCS genes are translated as a result of cytokine-induced activation as part of the JAK–STAT negative feedback loop. SOCS proteins bind JAKs or their receptors and act by (i) abolishing the kinase ability of JAK, (ii) abolishing the ability of JAK to bind to the receptor, (iii) blocking STATs from being recruited to the receptor, and (iv) mediating the ubiquitination of JAKs and STATs for degradation (124).

SOCS1–3 and CIS have been shown to negatively regulate GH-mediated signaling (Figure 5). SOCS2 appears to be the major SOCS-negative regulator of GH signaling as socs2−/− mice are 30–40% larger than WT littermates while other SOCS knockouts (KOs) do not significantly affect size (124, 125). The SOCS proteins contain a conserved SOCS box (126, 127) that is located at the C-terminus which facilitates ubiquitin-mediated proteasomal degradation of their associated target proteins (128). As the SOCS box comprises (i) BC box that interacts with elongin B and C and the (ii) Cul box that recruits Cul5 in these protein complexes can associate with the RING-box protein 2 and other components to form the E3 ubiquitin ligase complex (128–130). Interestingly, the crystal structure of the SOCS2–Elongin B/C complex revealed that the C-terminus of the SOCS box and the N-terminus of the extended SH2 subdomain (ESS) can interact and maintain the stability of the SH2–SOCS box domain interaction (131). This finding shows that all three domains of SOCS2 (N-terminal ESS, SH2, and SOCS box) can undergo conformational changes and work together to channel their substrates to ubiquitin-mediated degradation. Many of the functional studies on SOCS proteins have focused on SOCS1 and SOCS3. These are the only SOCS that contain the kinase inhibitory region (KIR) at their N-terminal domain. The KIR is able to bind and block the catalytic cleft of JAK thereby inhibiting the ability of JAK kinase to phosphorylate its substrate and consequently inhibiting signaling (132–134). The importance of SOCS2-mediated degradation of GH has recently been underscored by a study showing that this was the key mechanism that causes an increased risk of developing lung cancer in individuals that carry an SNP in GHR resulting in the amino acid change P495T in the GHR ICD. This amino acid change was shown to cause a structural change that impaired binding of SOCS2 resulting in reduced degradation of GHR and extended signaling in response to GH (135).

Protein Tyrosine Phosphatases

Tyrosine phosphatases, as their name suggests, act to inhibit signaling by dephosphorylating their substrate. There are four groups of PTPs (based on their substrate recognition): (i) non-receptor PTPs such as SHP1 and SHP2, (ii) receptor tyrosine phosphatases such as CD45, (iii) dual-specificity phosphatases, and (iv) low molecular weight phosphatases (136). According to their subcellular localization, PTPs can affect either JAKs or STATs. Those that are located on the membrane or in the cytoplasm will act on JAKs whereas those that are localized to the nucleus act on STATs. Both the non-TM PTPs and receptor protein tyrosine phosphatases are cysteine based and recognize only tyrosine phosphorylated residues and not serine or threonine residues (137, 138).

Several PTPs have been implicated in regulating GH signaling including SHP1, SHP2, PTP-1B, and PTP-H1 (139–144). The well-studied SHP1 (PTPN6; also known as HCP, PTP1C, SH-PTP1, and Hcph) is generally expressed in hematopoietic cell lineages whereas SHP2 (PTPN11; also known as PTP1D, SYP, SH-PTP2,
The major negative regulation of growth hormone receptor (GHR) signaling. GH-activated GHR results in suppressor of cytokine signaling (SOCS) 2 binding to a phosphorylated tyrosine on the GHR intracellular domain. This blocks signal transducer and activator of transcription (STAT) 5 binding and induces ubiquitination of the GHR leading to targeted degradation of the receptor. SHP1 and SHP2 act to dephosphorylate and inactivate Janus kinase 2 and STATs, while SHP2 is known to also dephosphorylate the receptor.

and SH-PTP3) has ubiquitous expression. Both SHP1 and SHP2 have high sequence and domain homology whereby they contain two SH2 domains at their N-terminal region, denoted as N- and C-SH2 domains, and a PTP catalytic domain. They also possess a C-terminal tail with tyrosine residues that can be phosphorylated to regulate PTP activity (145, 146). Interestingly, SOCS1 can aid SHP1 in downregulating JAK–STAT signaling via the erythropoietin and PRLR. It has been proposed that the activation of the
receptor by ligand binding recruits SHP1 to the JAK2–receptor complex and results in the phosphorylation of the C-terminus of SHP1 where the phosphorylated residues act as docking sites for the Grab2/SOCS1 complex to bind (147). SOCS1 is subsequently released and then binds to JAK2 to inhibit its kinase activity (147). This proposed mechanism suggests that negative regulators can associate with each other to regulate signaling.

Mouse studies with deficiency of SHP1 or SHP2 highlight the importance of these phosphatases. The motheaten phenotype is due to a splicing mutation in SHP1 causing an absence of detectable protein and mice that have severe disorders of hematopoietic cells resulting in death within 3 weeks after birth (148). Mice with a targeted deletion within the N-terminal SH2 domain result in embryonic lethality (149). Mutation of SHP2 accounts for more than half of the cases of Noonan syndrome, characterized by proportional short stature, facial dysmorphia, and heart disease (150). These mutations in SHP2 result in hyperactive phosphatase activity, notably with elevated basal activity and result in inhibition of GH-induced insulin-like growth factor-1 (IGF-1) production (143, 151). SHP2 has been shown to associate with a specific phosphorylated tyrosine residue in GHR with high affinity and mutation of this tyrosine to phenylalanine results in prolonged GH activation of STAT5 (140). Studies have shown an intriguing regulation of GHR signaling by IGF-1R, which suggested that IGF-1R positively regulates GH-mediated signaling by preventing PTP-1B suppression of GH activation of STAT5 (144).

### Protein Inhibitor of Activated STATs

Protein inhibitor of activated STATs are constitutively expressed, and, similar to SOCS, are involved in the negative feedback loop of cytokine-induced JAK–STAT signaling. Different PIAS proteins affect different STAT transcription factors. PIAS proteins may affect signaling by (i) inhibiting the DNA-binding activity of STATs, (ii) substrate SUMOylation, or (iii) recruit other transcriptional co-repressors. While PIASs are able to associate with STATs, they are also able to regulate other transcription factors including SMADs, androgen receptor, c-JUN, and p53. The PIAS family of transcriptional co-regulators consist of PIAS1, PIASxα, PIASxβ, PIAS3, PIAS3L (PIAS3β), PIASγ, and PIASyE6. Although PIAS proteins are known as negative regulators of JAK–STAT signaling, their specific role in GH-mediated signaling is not well studied.

### LNK

The LNK adaptor protein is also involved in downstream JAK–STAT signaling. LNK is encoded by the SH2B3 gene and is part of the family of SH2-containing adaptor protein that includes SH2B (or SH2B1) and APS (or SH2B2). However, these adaptor proteins have different functions as the binding of SH2B or APS to JAK2 enhances its kinase activity whereas LNK binding to JAK2 inhibits its kinase activity (152). LNK is mainly expressed in hematopoietic cells and is known to be important for regulating a number of signaling pathways mediated by the TPR (MPL), erythropoietin receptor (EPOR), stem cell factor receptor (KIT and SCF), macrophage colony-stimulating factor receptor (CSF1R and C-FMS), and platelet-derived growth factor receptor (PDGFRB). Although LNK has been shown to be expressed in a range of tissue including muscle, brain, testis, and hematopoietic cells (153), its ability to regulate GHR signaling is currently not clear.

### PHYSIOLOGICAL ASPECTS OF GH/IGF-1 AXIS

The effects of cellular signaling from GHR activation are responsible for a vast array of important physiological roles. Growth hormone is secreted by the anterior pituitary gland and not only has a role in increasing bone length, bone density, and muscle mass during childhood and adolescence but also importantly in the regulation of metabolism of lipids, carbohydrates, and body water throughout life (Figure 6) (154). The effects of GH are exerted by binding to the GH receptors on target cells, which in turn stimulates the production and secretion of IGF-1 from many tissues, mainly the liver (155). Since 1957 when IGF-1 and IGF-2 were identified and first designated as “sulfation factors” (156), the interest in the study of these molecules that structurally resembled proinsulin increased, especially when IGF-1 was found to be the mediator of the anabolic and mitogenic activity of GH (157). IGFs were first named as somatomedins due to their concentration dependence by GH regulation. A subsequent isolation and amino acid sequence determination of two homogeneous polypeptides from purified non-suppressible insulin-like activity factors (158–160) established the current designation of these molecules as insulin-like growth factors (IGFs) 1 and 2 (161). IGF-1 is a 70 amino acid peptide with a molecular weight of 7,649 Da. It has the ability to bind to the insulin receptor, although with low affinity. Most IGF-1 is secreted by the liver and acts as an endocrine hormone, although it can be secreted by many other tissues (162). One of the main roles for which IGF-1 has promoted subsequent research is its involvement in growth and its relation to growth hormone. Exogenous IGF-1 was shown to stimulate growth when administered to hypophysectomized rats (163, 164). Furthermore, children with IGF-1 deficiency-primarily GH insensitivity or children with Laron syndrome who were treated with biosynthetic IGF-1 (165) showed increases in their serum alkaline phosphatase and serum procollagen and IGF-binding protein-3 (IGFBP-3) (165–167). This treatment was subsequently widely used in other parts of the world (168, 169). In terms of efficacy, GH and IGF-1 both stimulated linear growth but some variables including the greater growth deficit in infants with Laron syndrome than those with isolated growth hormone deficiency, insufficient IGF-1 dose, or the IGF-1 dependency on the GH-linked stem cell population of prechondrocytes made GH more efficient in terms of linear growth stimulation (170, 171). However, IGF-1 was shown to be an important growth-related hormone that has a GH-independent growth stimulating effects that in some cases acts synergistically with GH (172). On the other hand, as described later, GHR signaling has been shown to have growth promoting effects independent of IGF-1.

### GH/IGF-1 in Insulin Sensitivity and Obesity

The anti-insulin action of GH is very well established (173) as liver, skeletal muscle, and adipose tissue develop insulin resistance.
induced by GH administration (174–177). Liver IGF-1-deficient mice show a reduction of around 75% in circulating IGF-1 levels and as a consequence due to the lack of negative feedback, these mice have about a fourfold increase in GH production. These liver IGF-1-deficient mice were crossed with mice that express a mutant GH that acts as an antagonist, and the resulting mice showed improved insulin sensitivity and decreased blood glucose and insulin levels (175). An important function of GH besides the control of growth is to provide a mechanism to cope with periods of food deprivation. In this way, GH stimulates lipolysis and provides free fatty acids and glycerol as substrates for energy metabolism and also inhibits insulin-induced suppression of hepatic gluconeogenesis counteracting insulin action (178). IGF-1 binds mainly to IGF-1 receptors located in the skeletal muscle and/or hybrid insulin/IGF-1 receptors, and it has been postulated as the mediator of enhanced insulin action as it binds insulin receptors with very low affinity (179). The interaction between IGF-1 and GH effects has made it difficult to determine whether IGF-1’s effect is due to the enhancement of insulin action or the suppression of GH secretion (180). Some studies suggested phosphatidylinositol 3-kinase as the key enzyme involved in the regulation of glucose uptake into cells by GH (175, 181, 182) while others found this mechanism to be of low significance as these experiments have not been replicated in humans (176, 177). GH receptors and IGF-1 receptors are abundant on not only adipocytes but also preadipocytes, fibroblasts, various immune cells, and endothelial cells (183–188). The connection between GH and energy metabolism is not just restricted to the promotion of lipolysis or the prevention of the lipogenesis (189, 190) but GH together with IGF-1 plays a crucial role in preadipocyte proliferation, differentiation, and senescence (191–194). Moreover, GH action alters the level of adiponectin and leptin in the circulation, and these adipokines can at the same time, control the GH/IGF axis by modulating GH output from the pituitary gland (195). Furthermore, GH was found to induce the so-called “browning” of adipocytes by increasing the amount of beige adipocytes in the white adipose tissue and as a consequence, decreasing the store of excess lipid as white adipocytes, which may function as a protective mechanism against obesity (196). In obesity, the spontaneous (197, 198) and stimulated (199) pulsatile patterns of GH secretion governed by the hypothalamus are blunted, and the accumulation of abdominal adiposity, particularly visceral adipose tissue mass, was found to be a stronger negative determinant of GH secretion than other factors including age, sex, or generalized obesity (200–202). In relation to GHR expression, its level was found to be influenced by nutritional status (203). For instance, white adipose tissue from obese women showed to have a lower expression of total GHR mRNA compared with those from lean
women, and the expression of GHR mRNA was also found to be higher in visceral white adipose tissue than in subcutaneous white adipose tissue in the lean women group (204).

**GH/IGF-1 in Muscle and Bone**

The significance of the GH/IGF-1 axis in the muscular system was highlighted when it was found that calcineurin (CaN), a calcium-calmodulin-dependent protein phosphatase that activates slow isoform of troponin I and myoglobin genes, was regulated by IGF-1 and that inhibiting CaN blocked IGF-mediated hypertrophy of cultured skeletal muscle cells (205). In addition, as shown using an animal model of congestive heart failure (CHF), GH prevented the atrophy and the shift from slow-twitch fibers to fast-twitch and more fatigable glycolytic fibers which works as an adaptation mechanism of the skeletal muscle to a low cardiac output characterizing the muscle atrophy as a common sign of patients with advanced CHF (206). GH has been shown to promote the cell growth of the skeletal muscle by facilitating the fusion of myoblasts with nascent myotubes, and that IGF-1 expression in myotubes is not regulated by GH (207). On the other hand, IGF-1 has been implicated in skeletal muscle hypertrophy, attenuation of age-related skeletal muscle atrophy, and restoring and improvement of muscle mass when virally delivered (208). The diversity of actions of both components of this axis in promoting the growth of skeletal muscles characterized by hyperplastic and hypertrophic muscle fibers. GH was also found to promote an increase in mitochondrial oxidative capacity and abundance of several mitochondrial genes when acutely administered (209) while exogenous administration of IGF-1 was associated with a reduced susceptibility of dystrophic muscles to contraction-induced injury (210). In addition to the roles of the GH/IGF axis in pathological conditions of the muscular system, studies have reported an important role of the GH/IGF axis in physiological conditions of the tendon and skeletal muscle. Both circulating GH and IGF increase in response to exercise (211, 212) and although the IGF-1 response to exercise is not as pronounced as the GH one, it is not necessarily a consequence of GH release (213, 214) as it was shown by the fact that IGF-1 can rise in response to exercise in patients with pituitary insufficiency (212). Circulating GH consistently increases after high-intensity exercise in adult males (215), and its level was related to the central effort in the brain to perform exercise (216). In the same way, local levels of IGF-1 were also induced in the muscular tissue subjected to both long- and short-term loading (217–219).

In relation to the bone, IGF-1 is an important mediator of the effects of GH and modulates bone growth through its paracrine action in the growth plate (220) as it was demonstrated that the selective deletion of the igf1 gene in the liver and a consequent decrease in systemic IGF-1 did not affect the animal’s body and femoral growth (221). However, a targeted disruption of igf1 expression in mouse chondrocytes reduced bone length (222). GH may act directly on skeletal cells having IGF-1-independent effects on bone growth (223, 224). In this regard, IGF-1 effects are produced by the enhancement of the function of mature osteoblasts (225) and promotion of osteoblast differentiation (226) and bone formation (227–229). Furthermore, higher levels of IGF-1 are associated with higher bone mineral density in adult obese individuals (230).

**GH/IGF-1 Role in Liver Disease**

The liver has important roles related to the function of the GH/IGF-1 axis besides the production and secretion of IGF-1 induced by GH. It also has a role in the production of IGFBP-3 by Kupffer cells (231, 232). IGF-binding proteins (IGFBPs) antagonize the activity of IGFs due to their high affinity to the IGF-1 receptor (227). Of the six IGFBPs, IGFBP-3 is the major binding protein for IGF-1 that modulates its biological effects (233). More than 80% of the circulating IGF-1 forms a complex with IGFBP-3 and the acid-labile subunit (ALS), which prolongs the half-life of serum IGF-1 (227, 234). Furthermore, IGFBP-3 levels are directly and indirectly modulated by GH and IGF-1 (232, 235) and are altered by nutritional deficiencies and liver function (236, 237).

Chronic liver disease (CLD) has been shown to correlate with high IGFBP-1 and low IGFBP-3, with IGFBP-3 being a major limiting factor for the reported low circulating IGF-1 levels (237). A similar observation was reported showing a significant relation between cirrhosis and circulating and venous ALS levels, which were decreased in relation to liver dysfunction (238). In non-alcoholic fatty liver disease (NAFLD) and advanced fibrosis, it was shown that the levels of GH, IGF-1, and IGFBP-3 varied according to the severity of the steatosis, which differed from the variation in samples taken from patients with hepatitis C virus-related CLD (239). The same study reported that patients with NAFLD and advanced fibrosis had high levels of GH and low levels of IGF-1 and IGFBP-3 (239). However, patients with NAFLD have significantly lower levels of serum GH in comparison with controls (240). This is not the case in cirrhotic patients where GH levels in serum were reported to be elevated (237) as the GH secretion rate was found to be increased (241). On the other hand, as IGF-1 and IGFBP-3 are regulated by GH secretion, the lack of negative feedback in cirrhotic patients with low levels of IGF-1 may be the cause of the exaggerated secretion of GH (239).

**GH/IGF-1 in Aging and Age-Related Diseases**

Circulating GH/IGF-1 levels peak in the second decade of life (242, 243) with this axis being the main regulator of postnatal growth while modulating other important physiological processes as well (244). Subsequently, secretion of GH and IGF-1 rapidly declines to very low levels in people aged 60 years or more, an event that was named “somatopause” (242, 245). This fact supported related studies that led to the belief that recombinant human GH was a potent antiaging agent. However, it was later found that while the effects on body composition from rhGH treatment were minor, adverse effects were significant and include the development of diabetes mellitus (246). On the other hand, decreasing GH/IGF signaling in various species including mice extended their lifespan (247), which was also related to a reduced risk of several age-related diseases including cancer (248). In a study of people with GHR deficiency, individuals showed IGF-1 deficiency and appeared to be protected against age-related diseases (249). It
is interesting to note that although KO mice for GH receptor/GH binding protein and for GH-releasing hormone showed an extended longevity (250, 251), this effect was not observed when using targeted deletion of the GH receptor in the liver, muscle, or adipose tissue (Table 3) (252). As low levels of GH/IGF were also reported to delay puberty and reproduction in KO models, it seems feasible that this axis may be working by shifting a “biological timer” and delaying aging as a consequence, which may defer as well the arrival of age-related diseases (253). In contrast to the animal models of the absence of GHR signaling, humans with GHR deficiency do not live longer; however, the interpretation of this is complicated by a high rate of deaths caused by alcohol toxicity, liver cirrhosis, convulsive disorders, and other non-age-related deaths such as accidents (249). A recent study investigating a common polymorphism resulting in exon 3-deleted GHR and resulting in increased GH sensitivity found that this polymorphism also correlated with a striking increase in life span in males of around 10 years (113).

As GH/IGF signaling induces growth mechanisms, inhibiting this signaling should suppress cell proliferation and a reduction in the cancer risk; however, other important mechanisms that may be affected by this process include a decrease in immune responses and reduced favorable metabolic adjustments (266). Moreover, being the process of aging characterized by a low-grade inflammation that is linked to several age-related diseases (267), the inhibition of the mechanisms that lead to it may consequently affect the development of these pathologies. According to these data, using GH antagonists or somatostatin analogs should slow aging (268). Currently, these drugs are being used for the treatment of acromegaly. Although these drugs show beneficial effects, such as somatostatin analogs, which normalize IGF-1 levels in around 45% of treated patients as is the case for lanreotide (269), they have also been reported to inhibit insulin secretion triggering the development of diabetes mellitus and aggravating the insulin resistance found in acromegalic patients (268, 270). Moreover, they have shown to produce other major adverse effects on the gastrointestinal tract (271). Therefore, it becomes necessary to understand the process of aging as a whole to detect the best target for treating age-related diseases.

**GHR IN CANCER**

GH and its specific receptor, GHR, are involved in multiple biological and physiological actions contributing to cell proliferation and differentiation. Dysregulation of GH–IGF-1 axis can amplify the synergistic effect of GH and IGF-1 to promote uncontrolled cell proliferation, cell movement, angiogenesis, and suppress apoptosis to increase risk of neoplasia (272). The excessive production of GH and associated complications has been studied long before its broader role in human health was discovered. Acromegaly is an endocrine condition, which is manifested with excess secretion of pituitary GH accompanied by an elevated level of circulatory IGF-1 (273). This is usually associated with high mortality and morbidity, mostly due to cardiovascular and/or respiratory diseases, renal failure, and elevated risk of multiple cancers especially colorectal cancer (274–277). A review of over 300 case-control and cohort studied used final height as an indication of GH–IGF-1 action and found that individuals over 175 cm have a 20% higher chance of developing prostate cancer, a 22 and 20–60% higher chance of breast and colorectal cancers, respectively, when compared with individuals below 160 cm (278, 279). Also, another study of 14-year-old females found that girls in the top fifth of height have an adjusted relative risk of over 1.5 for breast cancer, exceeding BMI and age of menarche as examined risk factors in the study (280). In addition, meta-analysis of published research investigating the association of IGF-1–IGF-2 and their binding proteins IGFBP-1–6 with prostate cancer confirmed that elevated circulating level of IGF-1 positively correlates with higher prostate cancer risk (281). On the other hand, this study found no or little evidence for the association of IGF-2, IGFBP-1, -2, and -3 with increased prostate cancer risk. In stark contrast, GHR-deficient individuals show a lack of deaths from cancer (249). A recent meta-analysis showed that increased height associated with an increased risk of lung cancer (282). The link between GHR signaling and lung cancer has been shown in two independent genetic studies that identified an SNP in GHR that correlated with an increased risk of lung cancer (283, 284). Recently, a study showed that functional consequence of this GHR SNP was an impaired interaction with SOCS2 resulting in an extended signaling following GH stimulation (135).

The link between acromegaly and increased risk of certain diseases especially colorectal cancers is well established, and there is a consensus on this issue even though there are some studies reporting contradictory results (285). However, the extent of this association is unclear since some studies have reported a 7.6-fold increase in the rate of colorectal cancers in acromegalic patients compared with control groups (275), whereas another study has reported as low as twofold increased risk of colorectal cancer in acromegalic patients (286, 287). Furthermore, a recent study investigating the prevalence of malignancies among 160 acromegalic patients over the period of 32 years using mammography, colonoscopy, thyroid, and prostate ultrasonography found thyroid cancer as the most frequent cancer (n = 17, 10.6%) followed by breast and colorectal cancers (288).

GH has been prescribed for children with GH deficiency since late 1950s using hormone extracted from the pituitary gland (289), and it was successfully produced in 1985 using recombinant DNA technology and approved to be administered for treatment of various disorders (290). However, in the past couple of decades, there has been a growing debate on GH treatment and its diabetogenic effects, impaired skeletal growth, and increased risk of de novo or recurrent cancers (272). Long-term survival of childhood cancer patients who have gone under total body or cranial irradiation in preparation for bone marrow transplantation or as a part of treatment for brain tumors or acute lymphoblastic leukemia are at higher risk of developing GH deficiency (285, 291). Although some initial studies reported recurrent brain tumors as a frequent cause of death in children treated with GH (292), a study that followed 180 children treated with GH who had brain tumors concluded that there was not a substantial trend in relative risk of recurrence with cumulative time for which GH treatment had been administrated and GH does not result in elevated risk of recurrent brain tumors (293). However, the study also suggested continued surveillance based on the rising trend
in mortality relative risks with longer follow-ups. Initial studies had reported leukemia incidences in children treated with GH replacement in Japan (294, 295); however, later follow-up studies were unsuccessful in establishing a link between GH therapy and leukemia when patients with existing risk factors were excluded (296). Another comprehensive study from Genentech’s National Cooperative Growth Study examined 40,000 children undergoing GH therapy with prolonged follow-ups and compared them to age-matched general public without known leukemia risk factors and showed a comparable incidence of leukemia for GH recipients (297, 298).

Growth hormone receptor has in some settings been observed to have a high degree of localization to the nucleus (272), and this nuclear localization has been shown to be induced by GH (299, 300). This nuclear localization has particularly been observed in proliferating cells including a range of different cancers such as colorectal carcinoma, melanoma, uterine cervical neoplasms, breast cancer, and hepatocellular carcinoma. Nuclear localized GHR has been observed in a number of species such as pig (300), rat (299), and fish (301). By targeting the GHR to the nucleus by fusing a nuclear localization signal to the receptor, it was found in the absence of GH that several genes known to be involved in oncogenesis were upregulated, and further studies provided evidence that the GHR can bind to a transcriptional regulator (299, 302). Studies also suggest that autocrine GH production may play an important role in cancer (272).

**GH SIGNALING MODEL MICE**

Gene KO (Table 2) and targeted mutant GHR mouse models (Table 3) have enabled us to better understand the role of GH signaling in postnatal growth and development. Hepatocytes generate the majority of circulating IGF-1 that is found in the blood. As IGF-1 expression is induced as a result of GH binding to GHR, hepatic IGF-1 levels are predominantly regulated by GH that is produced by the pituitary. The Somatomedin hypothesis states that postnatal growth that is induced by GH is mediated by IGF-1 (previously known as Somatomedin C or sulfation factor) in an endocrine manner (156). However, studies have shown that postnatal growth is actually mediated by IGF-1 (299, 302). Studies also suggest that autocrine GH production may play an important role in cancer (272).

| GHR knockout/mutations | Effects on signaling |
|------------------------|---------------------|
| Ghr−/− (GHR knockout) | No GH-mediated signaling (254, 255) |
| GhrΔBox1−/− (mutation of prolines in the Box1 motif) | No janus kinase–signal transducer and activator of transcription (STAT) signaling but Src/ERK signaling can occur (110) |
| Ghr569 (truncation at residue 569) | STAT5-signaling deficient (255, 256) |
| Ghr569 (truncation at residue 569 and amino acid mutation of residues Y339/545 to F539/545) | STAT5 activation markedly impaired (255, 256) |

**TABLE 3 | Growth hormone receptor (GHR) conditional knockout (KO) mice.**

| GHRKO | Conditional GHR KO | Effects |
|-------|-------------------|---------|
| Abb-cre: liver-specific GHR deletion | Greater than 90% reduction in circulating insulin-like growth factor-1 (IGF-1), however no effect on total body or bone growth. Increased IGF-1 mRNA in skeletal muscle. Liver steatosis, insulin resistance, glucose intolerance, increased circulating free fatty acids, leptin, resistin, and adiponectin (257–260) |
| Rip-cre: β cell deletion | Impaired glucose-stimulated insulin secretion (261) |
| MCK-cre: postnatal skeletal muscle deletion | Protection against high-fat diet-induced metabolic deterioration, sex-dependent effects as male mice show improved fasting glucose, insulin, and glucose tolerance while female mice were not altered (258, 262, 263) |
| mef-2c–73k: skeletal muscle deletion | Impaired skeletal muscle development, insulin resistance, and glucose intolerance (264) |
| Fabp4-c: adipose tissue deletion | Increase in adipose tissue and decreased circulating adipins (258, 265) |
and signaling, while still allowing signaling to occur via the SFK–ERK1/2 pathway have obstructed growth with a similar phenotype observed in mice with ghr KO (109, 110). A similar growth phenotype is also observed in mice with a truncated ghr (at amino acid position 391), which eliminates all GH-mediated STAT5 signaling while still allowing for JAK2, STAT1, and STAT3 activation (110). These mouse models demonstrate the crucial involvement of JAK2 and STAT5 in regulating postnatal growth by GH. However, they also show that GH-mediated SFK signaling does not play a significant role in regulating growth. Nevertheless, it is possible that the relative levels of JAK2 or SFKs in certain cell types may be a determinant as to which kinase would be dominant for signaling (110).

**CONCLUDING REMARKS**

Although we have learnt a vast amount on the molecular mechanism of GHR activation, signaling, physiological aspects, and roles of GH signaling in disease states, there is still much to learn. In particular, this is due to the wide range of physiological roles that GH has, making it an important player in many biological conditions and diseases. At the molecular and cellular level, the activation and role of SFK signaling is still currently not well understood. As our knowledge of the molecular signaling nature of GHR increases, our ability to specifically target the receptor and its signaling pathways for a diverse range of therapeutic purposes should also increase.

**AUTHOR CONTRIBUTIONS**

All the authors contributed equally. All the authors contributed to drafting and editing the manuscript. All the authors contributed to figures and tables.

**FUNDING**

This work was supported by the project grant APP1084797 from the National Health and Medical Research Council (NHMRC) of Australia. The authors would like to acknowledge the support from The University of Queensland Diamantina Institute. CMML was supported by Hardy Brothers Scholarship for Research in Blood Cancer at the UQ Diamantina Institute.
28. Caldenhoven E, van Dijk T, Raaijmakers JA, Lammers JW, Koenderman L, De Brizzi MF, Aronica MG, Rosso A, Bagnara GP, Yarden Y, Pegoraro L.

29. Mui AL, Wakao H, O'Farrell AM, Harada N, Miyajima A. Interleukin-3, a factor by interleukin-5. Groot RP. Activation of the STAT3/acute phase response factor transcription factor by interleukin-5. J Biol Chem (1995) 271(7):3562–7. doi:10.1074/jbc.271.7.3562

30. Rosen RL, Winstone KD, Chen G, Liu X, Hennighausen L, Finblom DS. Granulocyte-macrophage colony-stimulating factor preferentially activates the 94-kD STAT5A and an 80-kD STAT5A isoform in human peripheral blood mononuclear leukocytes. Blood (1996) 89(4):1206–14.

31. Stahl N, Boulton TG, FarrugIELLA, Ip NY, Davis S, Withnall BA, et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science (1994) 263(5143):92–5. doi:10.1126/science.2722873

32. Guschin D, Rogers N, Briscoe J, Witthuhn B, Watling D, Horn F, et al. A signaling pathway and rapidly activates p93fes, STAT1 p91, and STAT3 p92 in polymorphonuclear leukocytes. J Biol Chem (1995) 271(19):9319–26. doi:10.1074/jbc.271.19.9319

33. Ernst M, Najdovska M, Grail D, Lundgren-May T, Buchert M, Tye H, et al. A role for the Janus kinases (Jaks).

34. Kodama H, Fukuda K, Pan J, Makino S, Baba A, Hori S, et al. Leukemia growth hormone receptor monoclonal antibodies. A specific conformational change may be required for full-length receptor signaling. J Biol Chem (1998) 273(9):5307–14. doi:10.1074/jbc.273.9.5307

35. Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ, et al. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (tropisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab (2001) 86(4):1716–23. doi:10.1210/jcem.86.4.74703

36. Gent J, van Kerkhof P, Roza M, Bu G, Stros GJ. Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis. Proc Natl Acad Sci U S A (2002) 99(15):9583–6. doi:10.1073/pnas.152294299

37. Gent J, Van Der Eijnden M, Van Kerkhof P, Stros GJ. Signaling and dimerization of the growth hormone receptor. Mol Endocrinol (2003) 17(5):967–75. doi:10.1210/me.2002-0261

38. Brown RJ, Adams JF, Pelekano RS, White JM, Lampe PA, Riley JK, et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol (2005) 12(9):814–21. doi:10.1038/nsmb977

39. Brooks AJ, Dai W, O’Mara ML, Abankwa D, Chhabra Y, Pelekano RA, et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science (2014) 344(6185):1249783. doi:10.1126/science.1249783

40. Liu Y, Jiang J, Leptik B, Zhang Y, Zinn KR, Frank SJ. Subdomain 2, not the transmembrane domain, determines the dimerization partner of growth hormone receptor and prolactin receptor. Endocrinology (2017) 158(10):3235–48. doi:10.1210/en.2017-00469

41. Bugge K, Papaleo E, Haxholm GW, Hopper JT, Robinson CV, Olsen JG, et al. A combined computational and structural model of the full-length human prolactin receptor. Nat Commun (2016) 7:11578. doi:10.1038/ncomms11578

42. Suzuki K, Nakajima H, Saito Y, Saito T, Leonard WJ, Iwamoto I. Janus kinase 3 (Jak3) is essential for common cytokine receptor gamma chain (gammac)-dependent signaling: comparative analysis of gammac, Jak3, and Jakc gamma(c) and Jak3 double-deficient mice. Cell (1998) 93(3):397–408. doi:10.1016/S0092-8674(00)01168-X

43. Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell (1998) 93(3):373–83. doi:10.1016/S0092-8674(00)01166-6

44. Walsh ST, Jevelis LM, Sylvester YE, Kossiakoff AA. Site2 binding energies of the regulatory step of growth hormone-induced receptor homodimerization. J Biol Chem (2003) 278(29):25960–70. doi:10.1074/jbc.M303339200

45. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA. Rational design of potent antagonists to the human growth hormone receptor. Science (1992) 256(5064):1677–80. doi:10.1126/science.256.5064.1677

46. Rowlinson SW, Behncken SN, Rowland JE, Clarkson RW, Strausburger CJ, WuZ, et al. Activation of chimeric and full-length growth hormone receptors by growth hormone receptor monoclonal antibodies. A specific conformational change may be required for full-length receptor signaling. J Biol Chem (1999) 274(9):5307–14. doi:10.1074/jbc.274.9.5307

47. Caldenhoven E, van Dijk T, Raaijmakers JA, Lammers JW, Koenderman L, De Brizzi MF, Aronica MG, Rosso A, Bagnara GP, Yarden Y, Pegoraro L.

48. Mui AL, Wakao H, O'Farrell AM, Harada N, Miyajima A. Interleukin-3, a factor by interleukin-5. Groot RP. Activation of the STAT3/acute phase response factor transcription factor by interleukin-5. J Biol Chem (1995) 271(7):3562–7. doi:10.1074/jbc.271.7.3562

49. Rosen RL, Winstone KD, Chen G, Liu X, Hennighausen L, Finblom DS. Granulocyte-macrophage colony-stimulating factor preferentially activates the 94-kD STAT5A and an 80-kD STAT5A isoform in human peripheral blood mononuclear leukocytes. Blood (1996) 89(4):1206–14.

50. Stahl N, Boulton TG, FarrugIELLA, Ip NY, Davis S, Withnall BA, et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science (1994) 263(5143):92–5. doi:10.1126/science.2722873
Dehkoda et al.  

Ják: mapping of the Jak3-receptor interaction domain. *EMBO J* (1999) 18(6):1549–58. doi:10.1093/emboj/18.6.1549

63. He F, Wang X, Jiang G, Guan R, Bernstein KJ, Sayeski PP, et al. Janus kinase 2 determinants for growth hormone receptor association, surface assembly, and signaling. *Mol Endocrinol* (2003) 17(11):2211–27. doi:10.1210/me.2003-0256

64. Frank SI, Yi W, Zhao Y, Goldsmith JE, Gilliland G, Jiang J, et al. Regions of the JAK2 tyrosine kinase required for coupling to the growth hormone receptor. *J Biol Chem* (1995) 270(24):14776–85. doi:10.1074/jbc.270.24.14776

65. Zhao Y, Wagner F, Frank SI, Kraft AS. The amino-terminal portion of the JAK2 protein kinase is necessary for binding and phosphorylation of the granulocyte-macrophage colony-stimulating factor receptor beta chain. *Cytokine* (1995) 7(23):1381–4. doi:10.1074/jbc.M707125200

66. Radtke S, Liau NP, Kershaw NJ. JAK1 takes a FERM hold of type II cytokine receptors. *Structure* (2008) 16(2):243–5. doi:10.1016/j.str.2008.01.005

67. Zhao Y, Wagner F, Frank SI, Kraft AS. The amino-terminal portion of the JAK2 pseudokinase domain is a dual-specificity protein kinase that negatively regulates cytokine signaling. *Nat Struct Mol Biol* (2011) 18(9):971–3. doi:10.1038/nsmb.2348

68. Bandaranayake RM, Ungureanu D, Shan Y, Shaw DE, Silvennoinen O, Hubbard SR. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. *Nat Struct Mol Biol* (2012) 19(8):754–9. doi:10.1038/nsmb.2348

69. Brooks AJ, Waters MJ. Rewriting the mechanism of JAK2 activation. *Cell Cycle* (2015) 14(3):285–6. doi:10.1080/15384101.2015.1006533

70. Lucet IS, Fantino E, Styles M, Bamert R, Patel O, Broughton SE, et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. *Blood* (2006) 107(1):176–83. doi:10.1182/blood-2005-06-2413

71. Lupardus PJ, Utsch M, Wallweber H, Bir Kohli P, Johnson AR, Eigenbrot C. Structure of the pseudokinase-domain kinases from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. *Proc Natl Acad Sci U S A* (2014) 111(22):8025–30. doi:10.1073/pnas.1411810111

72. Waters MJ, Brooks AJ, Chababy A. A new mechanism for growth hormone receptor activation of JAK2, and implications for related cytokine receptors. *JAKSTAT* (2014) 3:e29569. doi:10.4161/jkst.29569

73. Babon JJ, Lucet IS, Murphy JM, Nicola NA, Varghese LN. The molecular regulation of Janus kinase (JAK) activation. *Biochem J* (2014) 462(1):1–13. doi:10.1042/BJ20140712

74. Vainchenker W, Constantinescu NC. JAK/STAT signaling in hematological malignancies. *Oncogene* (2013) 32(21):2601–13. doi:10.1038/onc.2012.347

75. Frank SJ, Gilliland G, Kraft AS, Arnold CS. Interaction of the growth hormone receptor with the cytoplasmic domain of the JAK2 kinase. *Endocrinology* (1994) 135(5):2228–39. doi:10.1210/endo.135.5.7956946

76. Frank SJ, Gilliland G, Kraft AS, Arnold CS. Interaction of the growth hormone receptor with the cytoplasmic domain of the JAK2 tyrosine kinase. *Endocrinology* (1994) 135(5):2228–39. doi:10.1210/endo.135.5.7956946

77. Tanner JW, Chen W, Young RL, Longmore GD, Shaw AS. The conserved box-1 motif of cytokine receptors is required for association with Jak kinases. *J Biol Chem* (1995) 270(24):14776–85. doi:10.1074/jbc.270.24.14776

78. He K, Wang X, Jiang J, Guan R, Bernstein KJ, Sayeski PP, et al. Janus kinase 2 phosphorylation by a functional FERM domain for transformation and for expression of oncostatin-M receptor surface expression. *J Biol Chem* (2002) 277(13):11297–305. doi:10.1074/jbc.M100822200

79. McNally R, Toms AV, Eck MJ. Crystal structure of the FERM-SH2 module of human Jak2. *PLoS One* (2016) 11(5):e0156218. doi:10.1371/journal.pone.0156218

80. O’Shea JJ, Gadina M, Chen XM. Structure of a Janus kinase: molecular insights and prospects for optimizing a new class of immunosuppressants. *Blood* (2005) 106(3):765–6. doi:10.1182/blood-2005-05-1947

81. Silvennoinen O, Ungureanu D, Niranjan Y, Hammaren H, Bandaranayake R, Hubbard SR. New insights into the structure and function of the pseudokinase domain in JAK2. *Biochem Soc Trans* (2013) 41(4):1002–7. doi:10.1042/BST20130005

82. Saharinen P, Takalauma K, Silvennoinen O. Regulation of the JAK2 tyrosine kinase by its pseudokinase domain. *Mol Cell Biol* (2000) 20(10):3387–95. doi:10.1128/MCB.20.10.3387-3395.2000

83. Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. *J Biol Chem* (2002) 277(49):47954–63. doi:10.1074/jbc.M205156200

84. Saharinen P, Vihtonen M, Silvennoinen O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. *Mol Biol Cell* (2003) 14(9):3468–80. doi:10.1091/mbc.E2-02-0342

85. Ungureanu D, Wu J, Pekkalka T, Niranjan Y, Young C, Jensen ON, et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. *Nat Struct Mol Biol* (2011) 18(9):971–3. doi:10.1038/nsmb.2348
116. Fresno Vara JA, Carretero MV, Geronimo H, Ballmer-Hofer K, Martin-Perez J. Chin H, Arai A, Wakao H, Kamiyama R, Miyasaka N, Miura O. Lyn physically interacts with the erythropoietin receptor.

115. Ben-Avraham D, Govindaraju DR, Budagov T, Fradin D, Durda P, Liu B, et al. Src-CrkII-C3G-dependent activation of Rap1 GTPase.

114. Ling L, Zhu T, Lobie PE. Identification of a JAK2-independent pathway regulating Rap1 activity.

113. Barclay JL, Kerr LM, Arthur L, Rowland JE, Nelson CN, Ishikawa M, et al. Src-family kinases: rheostats of immune cell signaling.

112. Rowlinson SW, Yoshizato H, Barclay JL, Brooks AJ, Behncken SN, Kerr LM, et al. The GHR associates with the erythropoietin receptor and may play a role in activation of Stat1 pathway.

111. Lowell CA. Src-family kinases: rheostats of immune cell signaling.

110. Manabe N, Kubota Y, Kitanaka A, Ohnishi H, Taminato T, Tanaka T. Src kinase is essential for erythropoietin-induced differentiation of J2E erythroid progenitors.

109. Liu W, Kawahara M, Ueda H, Nagamune T. The influence of domain structures on the signal transduction of chimeric receptors derived from the erythropoietin receptor.

108. Boggon TJ, Eck MJ. Structure and regulation of Src family kinases. Oncogene (2004) 23(48):7918–27. doi:10.1080/0261537041000173766

107. Ferrara P, Piantelli M. Cis3/Socs3 inhibits Janus kinase 2 kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain.

106. Hilton DJ, Richardson RT, Alexander WS, Viney EM, Willson TA, Sprigg NS, et al. Twenty proteins containing a C-terminal SOCS box form five structural classes.

105. Engen JR, Wales TE, Hochrein JM, Meyn MA, II, Bunu O, Oskan S, Bahar I, et al. Stimulation of c-Src by prolactin is independent of Jak2.

104. Metcalf D, Greenhalgh CJ, Viney E, Willson TA, Starr R, Nicola NA, et al. Gagantism in mice lacking suppressor of cytokine signalling-2. Nature (2000) 405(6790):1069–73. doi:10.1038/35016611

103. Kershaw NJ, Murphy JM, Liau NP, Varghese LN, Laktyushin A, Whitlock EL, et al. Identification of protein tyrosine phosphatases with specificity for tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B.

102. Metcalf D, Greenhalgh CJ, Viney E, Willson TA, Starr R, Nicola NA, et al. Gagantism in mice lacking suppressor of cytokine signalling-2. Nature (2000) 405(6790):1069–73. doi:10.1038/35016611

101. Kershaw NJ, Murphy JM, Liau NP, Varghese LN, Laktyushin A, Whitlock EL, et al. Identification of protein tyrosine phosphatases with specificity for tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B.

100. Hilton DJ, Richardson RT, Alexander WS, Viney EM, Willson TA, Sprigg NS, et al. Twenty proteins containing a C-terminal SOCS box form five structural classes.

99. Manabe N, Kubota Y, Kitanaka A, Ohnishi H, Taminato T, Tanaka T. Src kinase is essential for erythropoietin-induced differentiation of J2E erythroid progenitors.

98. Hilton DJ, Richardson RT, Alexander WS, Viney EM, Willson TA, Sprigg NS, et al. Twenty proteins containing a C-terminal SOCS box form five structural classes.
factor I release via growth hormone-induced ERK hyperactivation, which contributes to short stature. Proc Natl Acad Sci USA (2012) 109(11):4257–62. doi:10.1073/pnas.1119803109

144. Yan Y, Zhang Y, Buckels A, Paterson AJ, Jiang J, Clemens TL, et al. IGF-1R modulation of acute GH-induced STAT5 signaling: role of protein tyrosine phosphatase activity. Mol Endocrinol (2013) 27(11):1969–79. doi:10.1210/me.2013-1178

145. Bennett AM, Tang TL, Sugimoto S, Walsh CT, Neel BG. Protein-tyrosine phosphatase SHPPTP2 couples platelet-derived growth factor receptor beta to Ras. Proc Natl Acad Sci U S A (1994) 91(15):7335–9. doi:10.1073/pnas.91.15.7335

146. Lorenz U, Ravichandran KS, Pei D, Walsh CT, Burakoff SJ, Neel BG. Lck-dependent tyrosyl phosphorylation of the protein tyrosine phosphatase SH-PTP1 in murine T cells. Mol Cell Biol (1994) 14(3):1824–34. doi:10.1128/MCB.14.3.1824

147. Minoo P, Zadeh MM, Rottapel R, Lebrun JJ, Ali S. A novel SHP-1/Grb2-dependent mechanism of negative regulation of cytokine-receptor signaling: contribution of SHP-1 C-terminal tyrosines in cytokine signaling. Blood (2004) 103(4):1398–407. doi:10.1182/blood-2003-07-2617

148. Tsui FW, Martin A, Wang J, Tsui HW. Investigations into the regulation and function of the SH2 domain-containing protein-tyrosine phosphatase, SHP-1. Immunol Rev (2006) 205(1–2):127–36. doi:10.1111/j.0855-4679.2006.tb00323.x

149. Saxton TM, Henkemeyer M, Gasca S, Shen R, Rossi DJ, Shalaby F, et al. Abnormal mesodermal patterning in mouse embryos mutant for the SH2-tyrosine phosphatase Shp-2. EMBO J (1997) 16(9):2352–64. doi:10.1093/emboj/16.9.2352

150. Tartaglia M, Meher EL, Goldberg R, Zamponi G, Brunner HG, Kremer H, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet (2001) 29(4):465–8. doi:10.1038/ng772

151. Keilhack H, David FS, McGregor M, Cantley LC, Neel BG. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem (2005) 280(35):30984–93. doi:10.1074/jbc.M504699200

152. Carter-So C, Schwartz J, Argetsinger LS. Growth hormone signaling pathways. Growth Horm IGF Res (2016) 28:11–5. doi:10.1016/j.ghirse.2015.09.002

153. Gery S, Koeppfl HP. Role of the adaptor protein LNK in normal and malignant hematopoiesis. Oncogene (2013) 32(26):3111–8. doi:10.1038/onc.2012.435

154. Melmed S, Polonsky KS, Larsen PR, Kronenberg H. Williams textbook of endocrinology. Philadelphia: Elsevier (2015).

155. Schwanzer JC, Hauri C, Zapf J, Frosch ER. Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status. Endocrinology (1985) 113(1):297–305. doi:10.1210/endo-113-1-297

156. Dujardin WH, Hall K, Raben MS, Salmon WD Jr, van den Brande JL, van der Val JT. Somatomedin: proposed designation for sulphation factor. Nature (1980) 285(5753):107. doi:10.1038/285107a0

157. Laron Z. Insulin-like growth factor 1 (IGF-1): a growth hormone. Endocr Rev (1998) 19(1):55–79. doi:10.1210/edrv.19.1.3024

158. Laron Z. Insulin-like growth factor I (IGF-1): a growth hormone. Mol Pathol (2001) 54(5):311–6. doi:10.1116/imp.54.5.311

159. Clemmons DR. Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary (2002) 5(3):181–3. doi:10.1023/A:1023321421760

160. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC. Growth hormone and bone. Endocr Rev (1998) 19(1):55–79. doi:10.1210/edrv.19.1.3024

161. Rinderknecht E, Humbel RE. Amino-terminal sequences of two polypeptides from human serum with nonsuppressible insulin-like and cell-growth-promoting activity. Proc Natl Acad Sci USA (1976) 73(7):2365–9.

162. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem (1978) 253(8):2769–76.

163. Rinderknecht E, Humbel RE. Primary structure of human insulin-like growth factor II. FEBS Lett (1978) 89(2):283–6. doi:10.1016/0014-5793(78)80237-3

164. Rinderknecht E, Humbel RE. Amino-terminal sequences of two polypeptides from human serum with nonsuppressible insulin-like and cell-growth-promoting activities: evidence for structural homology with insulin B chain. Proc Natl Acad Sci USA (1978) 73(12):4379–81.

165. D’Ercole AJ, Applewhite GT, Underwood LE. Evidence that somatomedin C contributes to short stature. Proc Natl Acad Sci USA (1980) 75(12):315–28. doi:10.1073/pnas.80.12.315

166. Schoenle E, Zapf I, Humbel RE, Frosch ER. Insulin-like growth factor I stimulates growth in hypophysectomized rats. Nature (1982) 296(5854):252–3. doi:10.1038/296252a0

167. Laron Z, Klinger B, Jentz LT, Silbergeld A, Laron Z. Long-term treatment of Laron type dwarfs with insulin-like growth factor I increases serum insulin-like growth factor-binding protein-3 in the absence of growth hormone activity. Acta Endocrinol (Copenh) (1993) 128(2):144–9.

168. Tagliaferri M, Scacchi M, Pincelli AI, Berselli ME, Silvestri P, Montesano A, et al. Metabolic effects of biosynthetic growth hormone treatment in severely energy-restricted obese women. Int J Obes Relat Metab Disord (1998) 22(9):836–41. doi:10.1038/sj.ijo.0800669

169. Jentz LT, Silbergeld A, Laron Z. Insulin-like growth factor I is the growth hormone. Proc Natl Acad Sci USA (1985) 82(13):4889–93. doi:10.1073/pnas.82.13.4889

170. Barbour LA, Mizanoor Rahman S, Gurevich I, Leitner JW, Fischer SJ, Roper MD, et al. Evidence against a role for insulin-signaling proteins PI 3-kinase and Akt in insulin resistance in human skeletal muscle induced by short-term GH infusion. Am J Physiol Endocrinol Metab (2005) 288(1):E194–9. doi:10.1152/ajpendo.00149.2004

171. Tschöp M, Schütz E, Bihain JE, Schaffner C, Doerr HD, Wirtz S, et al. Leptin improves glycemic control in type II diabetes. J Clin Endocrinol Metab (1996) 81(9):3312–7. doi:10.1210/jcem.81.9.8784084

172. Barbour LA, Mizanoor Rahman S, Gurevich I, Leitner JW, Fischer SJ, Roper MD, et al. Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. J Biol Chem (2005) 280(45):37489–94. doi:10.1074/jbc.M506967200

173. Del Rincon JP, Iida K, Gaylinn BD, McCurdy CE, Leitner JW, Barbour LA, et al. Growth hormone regulation of p85alpha expression and phosphoinositol
3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. *Diabetes* (2007) 56(6):1638–46. doi:10.2337/db06-0299

183. Fisker S, Kristensen K, Rosenfalk AM, Pedersen SB, Ebdrup L, Richelsen B, et al. Gene expression of a truncated and the full-length growth hormone (GH) receptor in subcutaneous fat and skeletal muscle in GH-deficient adults: impact of GH treatment. *J Clin Endocrinol Metab* (2001) 86(2):792–6. doi:10.1210/jcem.86.2.7250

184. Fisker S, Hansen B, Fuglsang J, Kristensen K, Ovesen P, Orskov H, et al. Gene expression of the GH receptor in subcutaneous and intraabdominal fat in healthy females: relationship to GH-binding protein. *Eur J Endocrinol* (2004) 150(6):773–7. doi:10.1530/eje.1.1500773

185. Fleenor D, Arumugam R, Freemark M. Growth hormone and prolactin receptors in adipogenesis: STAT-5 activation, suppressors of cytokine signaling, and regulation of insulin-like growth factor I. *Horm Res* (2006) 66(3):101–10. doi:10.1159/000093667

186. Lyeh E, Kim HJ, Kim M, Lee JK, Park KS, Yoo KY, et al. Dose-specific or dose-dependent effect of growth hormone treatment on the proliferation and differentiation of cultured neuronal cells. *Horm Res* (2007) 17(4):315–22. doi:10.1016/j.horm.2007.03.002

187. Hattori N. Expression, regulation and biological actions of growth hormone (GH) and ghrelin in the immune system. *Growth Horm IGF Res* (2009) 19(3):187–97. doi:10.1016/j.ghir.2008.12.001

188. Lu C, Kumar PA, Fan Y, Sperling MA, Menon RK. A novel effect of growth hormone on macrophage modulation in macrophage-dependent adipocyte differentiation. *Endocrinology* (2010) 151(5):2189–99. doi:10.1210/en.2009-1194

189. Richelsen B, Pedersen SB, Borglum JD, Moller-Pedersen T, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. *Endocr Rev* (2009) 30(2):152–77. doi:10.1210/er.2008-0027

190. Nair SY, Lobie PE. The mechanism of effect of growth hormone on preadipocyte and adipocyte function. *Obes Rev* (2000) 1(2):73–86. doi:10.1046/j.1467-789x.2000.00015.x

191. Tekkonia T, Lenburg M, Thomou T, Giorgadze N, Frampton G, Pirtskhalava T, et al. Identification of depot-specific human fat cell progenitors through distinct expression profiles and developmental gene patterns. *Am J Physiol Endocrinol Metab* (2007) 292(1):E298–307. doi:10.1152/ajpendo.00202.2006

192. Cartwright MJ, Schlauch K, Lenburg ME, Tekkonia T, Pirtskhalava T, Cartwright A, et al. Aging, depot origin, and preadipocyte gene expression. *J Gerontol A Biol Sci Med Sci* (2010) 65(3):242–51. doi:10.1093/gerona/glp213

193. Garten A, Schuster S, Kiess W. The insulin-like growth factors in adipogenesis and obesity. *Endocrinology* (2011) 150(6):773–7. doi:10.1210/jcem.2010.0773

194. Goodyer CG, Zogopoulos G, Schwartzbauer G, Zheng H, Hendy GN, Menon RK. Organization and evolution of the human growth hormone receptor gene 5′-flanking region. *Endocrinology* (2001) 142(5):1923–34. doi:10.1210/endo.142.5.8170

195. Hameed M, Lange KH, Andersen JL, Schjerling P, Kjaer M, Harridge SD, et al. Expression of the GH receptor in subcutaneous and intraabdominal fat in healthy subjects and patients with growth hormone deficiency. *Eur J Clin Invest* (1990) 20(3):285–95. doi:10.1111/j.1365-2362.1990.tb01857.x

196. Wallace JD, Cuneo RC, Baxter R, Orskov H, Keay N, Pentecost C, et al. GH/IGF-I axis and matrix adaptation of the musculotendinous unit during skeletal muscle growth: a potential test for GH abuse in sport. *Proc Natl Acad Sci U S A* (2006) 103(19):7315–20. doi:10.1073/pnas.0510033106

197. Roh J, Glick SM, Yalow RS, Bersan SA. Secretion of human growth hormone: physiologic and experimental modification. *Metabolism* (1963) 12:577–9.

198. Bang P, Brandt J, Degerblad M, Enberg G, Kaijser L, Thoren M, et al. Exercise-induced changes in insulin-like growth factor I and ghrelin in healthy subjects and patients with growth hormone deficiency. *Eur J Clin Invest* (1990) 20(3):285–92. doi:10.1111/j.1365-2362.1990.tb01857.x

199. Wallace JD, Yalow RS, Berson SA. Secretion of human growth hormone: mechanisms of pulsatile release. *J Clin Endocrinol Metab* (2006) 91(3):E499–505. doi:10.1136/medsci.2001.000260

200. Vahil M, Nikkari V, Tani J, Arvela N, Kohonen S, Hanninen O. Expression of IGFBP-3, IGFBP-4, IGFBP-5, and IGFBP-6 in human skeletal muscle and adipose tissue. *Frontiers in Endocrinology* (2018) 9:35. doi:10.3389/fendo.2018.00035
training on IGF-I mRNA expression in the muscles of elderly men. *J Physiol* (2004) 555(Pt 1):231–40. doi:10.1113/jphysiol.2003.051722

219. Heinemeier KM, Bjerrum SS, Schjøting P, Kjaer M. Expression of extracellular matrix components and related growth factors in human tendon and muscle after acute exercise. *Scand J Med Sci Sports* (2013) 23(3):e150–61. doi:10.1111/1600-0838.2011.01414.x

220. Schlechter NL, Russell SM, Spencer EM, Nicoll CS. Evidence suggesting that the direct growth-promoting effect of growth hormone on cartilage in vivo is mediated by local production of somatomedin. *Proc Natl Acad Sci U S A* (1986) 83(20):7932–4. doi:10.1073/pnas.83.20.7932

221. Y akar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, et al. Normal growth hormone, insulin-like growth factor-1, and insulinlike growth factor binding proteins: biological actions. *Endocr Rev* (1996) 17(4):818–27. doi:10.1210/en.17.4.818

222. Govoni KE, Lee SK, Chung YS, Behringer RR, Wergedal JE, Baylink DJ, et al. Disruption of insulin-like growth factor-1 expression in type Iphal collagen-expressing cells reduces bone length and width in mice. *Physiol Genomics* (2007) 30(3):354–62. doi:10.1152/physiogenomics.00022.2007

223. Wang J, Zhou J, Cheng CM, Kopchick JJ, Bonty CA. Evidence supporting dual, IGF-I-independent and IGF-I-dependent, roles for GH in promoting longitudinal bone growth. *J Endocrinol* (2004) 180(2):247–55. doi:10.1677/joe.0.1800247

224. Wu S, Yang W, De Luca F. Insulin-like growth factor-independent effects of growth hormone on growth plate chondrogenesis and longitudinal bone growth. *Endocrinology* (2015) 156(7):2541–51. doi:10.1210/endo.2014-1983

225. Walsh S, Jerfess CM, Stewart K, Beresford JN. IGF-I does not affect the proliferation or early osteogenic differentiation of human marrow stromal cells. *Bone* (2003) 33(1):80–9. doi:10.1016/S8756-3282(03)00165-0

226. Ochiai H, Okada S, Hoshi K, Yamashita H, Takato T, et al. Insulin/insulin-like growth factor-beta1 (TGF-beta1) administration suppresses osteoblast differentiation. *J Biol Chem* (2012) 287(27):22654–61. doi:10.1074/jbc.M111.279091

227. Yang J, Zhou J, Cheng CM, Kopchick JJ, Bondy CA. Evidence supporting dual, IGF-I-independent and IGF-I-dependent, roles for GH in promoting longitudinal bone growth. *J Endocrinol* (2004) 180(2):247–55. doi:10.1677/joe.0.1800247

228. Guntur AR, Rosen CJ. IGF-1 regulation of key signaling pathways in bone. *Bonekey Rep* (2017).

229. Yan J, Herzog JW, Tsang K, Brennan CA, Bower MA, Garrett WS, et al. Insulin growth factor-1 correlates with higher bone mineral density and lower inflammation status in obese adult subjects. *Proc Natl Acad Sci U S A* (2016) 113(47):E7554–63. doi:10.1073/pnas.1607235113

230. Vitale G, Barbieri M, Kamenetskaya M, Paolussi G. GH/IGF-I/insulin system in centenarians. *Mech Ageing Dev* (2016) 165(Pt B):107–14. doi:10.1016/j.mad.2016.12.001

231. Toogood AA, OE’Neill PA, Shalet SM. Beyond the somatopause: growth hormone deficiency in adults over the age of 60 years. *J Clin Endocrinol Metab* (1996) 81(2):460–5. doi:10.1210/jcem.81.2.8636250

232. Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. *Ann Intern Med* (2007) 146(2):104–15. doi:10.7326/0003-4819-146-2-20071160-00005

233. Fontana L, Partridge L, Longo VD. Extending healthy life span – from yeast to humans. *Science* (2010) 328(5976):321–6. doi:10.1126/science.1172539

234. Milsum S, Huffman DM, Barzilai N. The somatotropic axis in human aging: framework for the current state of knowledge and future research. *Cell Metab* (2016) 23(6):980–9. doi:10.1016/j.cmet.2016.05.014

235. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. *Sci Transl Med* (2011) 3(70):70ra13. doi:10.1126/scitranslmed.3001845

236. Coschigano KT, Clemmons DR, Bellush IJ, Kopchick JJ. Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. *Endocrinology* (2000) 141(7):2608–13. doi:10.1210/endo.141.7.75786

237. Coschigano KT, Holland AN, Riders ME, List EO, Flyvbjerg A, Kopchick JJ. Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. *Endocrinology* (2003) 144(9):7997–810. doi:10.1210/en.2003-0374

238. Bartke A, List EO, Kopchick JJ. The somatotropic axis and aging: benefits of endocrine defects. *Growth Horm IGF Res* (2016) 27:41–5. doi:10.1016/j.ghir.2016.02.002

239. Rincon M, Rudin E, Barzilai N. The insulin/IGF-1 signaling in mammals and its relevance to human longevity. *Exp Gerontol* (2005) 40(11):473–7. doi:10.1016/j.exger.2005.06.014
domain: assessment of growth parameters and phenotype. *Endocrinology* (2005) 146(12):5278–86. doi:10.1210/en.2005-0939

257. Vijayakumar A, Wu Y, Sun H, Vijayakumar A, Wu Y, Liu C, Sun H, Li X, Jedy Z, Liu C, et al. Targeted loss of growth hormone receptor gene-disrupted mice is sex dependent. *J Gerontol A Biol Sci Med Sci* (2015) 70(1):44–52. doi:10.1093/gerona/glu008

258. Li X, Bartke A, List EO, Berryman DE, Funk K, Longo V. Somatotropic signaling: trade-offs between direct and indirect effects of growth hormone receptor ablation on liver expression of xenobiotic metabolizing genes. *J Clin Endocrinol Metab* (1997) 82(6):1993–7. doi:10.1210/jcem.82.6.1993

259. Sacca L, Cittadini A, Fazio S. Growth-hormone and the heart. *Circulation* (2003) 107(6):774–8. doi:10.1161/01.CIR.0000062387.29383.86

260. Jenkinson RK, List EO, Berryman DE, Murrey JW, Kopchick JJ. The GH/IGF-I axis and colorectal cancer. *Best Pract Res Clin Endocrinol Metab* (2008) 22(4):573–93. doi:10.1016/j.bermanapre.2007.09.005

261. Wu Y, Liu C, Sun H, Vijayakumar A, Giglou PR, Qiao R, et al. Growth hormone receptor gene-disrupted mice. *Endocrinology* (2013) 154(5):1793–805. doi:10.1210/en.2013-0286

262. Vijayakumar A, Wu Y, Sun H, Li X, Jedy Z, Liu C, et al. Targeted loss of GHR signaling in mouse skeletal muscle protects against high-fat diet-induced metabolic deterioration. *Diabetes* (2012) 61(1):94–103. doi:10.2337/db11-0814

263. List EO, Berryman DE, Ikeno Y, Hubbard GR, Funk K, Comisford R, et al. Removal of growth hormone receptor (GHR) in muscle of male mice replicates some of the health benefits seen in global GHR−/− mice. *Aging (Albany NY)* (2015) 7(7):300–12. doi:10.18632/aging.100766

264. Mavalli MD, DiGregorio DJ, Fan Y, Riddle RC, Campbell KS, van Groen T, et al. Distinct growth hormone receptor signaling modes regulate skeletal muscle development and insulin sensitivity in mice. *J Clin Invest* (2010) 120(11):4007–20. doi:10.1172/JCI42447

265. List EO, Berryman DE, Funk K, Gosney ES, Jara A, Kelder B, et al. Expression of apoptosis-related genes in liver-specific growth hormone receptor gene-disrupted mice. *Mol Endocrinol* (2013) 27(3):524–35. doi:10.1210/me.2012-1330

266. Bartke A, Sun LY, Longo V. Somatotropic signaling: lessons from adipose-specific GH receptor gene-disrupted mice. *Endocrinology* (2009) 150(8):E942–50. doi:10.1210/ajpendo.00304.2013

267. Chhabra Y, Waters MJ, Brooks AJ. Role of the growth hormone–IGF-1 axis in biology. *Am J Physiol Endocrinol Metab* (2014) 305(8):E942–50. doi:10.1152/ajpendo.00304.2013

268. Junnila RK, List EO, Berryman DE, Murrey JW, Kopchick JJ. The GH/IGF-I axis and indirect effects of growth hormone receptor ablation on liver expression of xenobiotic metabolizing genes. *J Clin Endocrinol Metab* (2006) 91(6):2014–20. doi:10.1210/jc.2005-2363

269. Chanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P, et al. Distinct growth hormone receptor signaling modes regulate skeletal muscle development and insulin sensitivity in mice. *J Clin Invest* (2010) 120(11):4007–20. doi:10.1172/JCI42447

270. Bustin SA, Jenkins PJ. The growth hormone-insulin-like growth factor-I axis role of GH in adipose tissue: lessons from adipose-specific GH receptor gene-disrupted mice. *Endocrinology* (2015) 156(2):314–21. doi:10.1210/en.2014-2086

271. Lichanska AM, Waters MJ, Byers WS, Matsuo K, Kojima M, Takahata N, et al. Circulating insulin-like growth factor peptides and prostate cancer risk: a meta-analysis of case-control studies. *Int J Cancer* (2008) 123(10):2399–403. doi:10.1002/ijc.23938

272. Melmed S. Acromegaly pathogenesis and treatment. *J Clin Invest* (2009) 119(11):3189–202. doi:10.1172/JCI39375

273. Bustin SA, Jenkins PJ. The growth hormone-insulin-like growth factor-I axis role of GH in adipose tissue: lessons from adipose-specific GH receptor gene-disrupted mice. *Endocrinology* (2014) 155(5):1793–805. doi:10.1210/en.2013-0286

274. Sacca L, Cittadini A, Fazio S. Growth-hormone and the heart. *Circulation* (2003) 107(6):774–8. doi:10.1016/S0009-733X(03)00317-5

275. Jenkins PJ, Besser M. Clinical perspective: acromegaly and cancer: a problem. *Endocr Rev* (1994) 15(5):555–73. doi:10.1210/er.15.5.555

276. Jenkins PJ, Besser M. Clinical perspective: acromegaly and cancer: a problem. *Endocr Rev* (2001) 22(1):2935–41. doi:10.1210/jc.86.7.7634
298. Chae HW, Kim DH, Kim HS. Growth hormone treatment and risk of malignancy. Korean J Pediatr (2015) 58(2):41–6. doi:10.3345/kjp.2015.58.2.41

299. Conway-Campbell BL, Worrall JW, Bena J, Gordon D, Brown RJ, Lichanska AM, et al. Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesis. Proc Natl Acad Sci U S A (2007) 104(33):13331–6. doi:10.1073/pnas.0600181104

300. Lan HN, Hong P, Li RN, Shan AS, Zheng X. Growth hormone-specific induction of the nuclear localization of porcine growth hormone receptor in porcine hepatocytes. Domest Anim Endocrinol (2017) 61:39–47. doi:10.1016/j.domaniend.2017.05.003

301. Figueiredo MA, Boyle RT, Sandrini JZ, Varella AS Jr, Marins LE. High level of GHR nuclear translocation in skeletal muscle of a hyperplastic transgenic zebrafish. J Mol Endocrinol (2016) 56(1):47–54. doi:10.1530/JME-15-0185

302. Conway-Campbell BL, Brooks AJ, Robinson PJ, Palmiter RD, Brinster RL. Growth allometry of the organs in giant transgenic mice. J Cell Physiol (2015) 230(11):2796–806. doi:10.1002/jcp.25006

303. Liu JL, LeRoith D. Conditional knockout of mouse insulin-like growth factor-1 gene using the Cre/loxP system. Proc Soc Exp Biol Med (2000) 223(4):344–51. doi:10.3181/0031-9420.22349.x

304. Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci U S A (1999) 96(12):7088–92. doi:10.1073/pnas.96.12.7088

305. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell (1993) 75(1):73–82. doi:10.1016/S0092-8674(05)80085-6

306. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igfr1). Cell (1993) 75(1):59–72. doi:10.1016/0092-8674(93)80084-4

307. Powell-Braxton L, Hollingshead P, Warburton C, Pitts-Meek S, Waters MJ. The extracellular domain of the growth hormone receptor interacts with coactivator activator to promote cell proliferation. Mol Endocrinol (2008) 22(9):2190–202. doi:10.1210/me.2008-0128

308. Liu JL, Yakar S, LeRoith D. Conditional knockout of mouse insulin-like growth factor-1 gene using the Cre/loxP system. Proc Soc Exp Biol Med (2000) 223(4):344–51. doi:10.3181/0031-9420.22349.x

309. Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci U S A (1999) 96(12):7088–92. doi:10.1073/pnas.96.12.7088

310. Lan HN, Hong P, Li RN, Shan AS, Zheng X. Growth hormone-specific induction of the nuclear localization of porcine growth hormone receptor in porcine hepatocytes. Domest Anim Endocrinol (2017) 61:39–47. doi:10.1016/j.domaniend.2017.05.003

311. Behringer RR, Lewin TM, Quaife CJ, Palmiter RD, Brinster RL, D’Ercole AJ. Expression of insulin-like growth factor I stimulates normal somatic growth in growth hormone-deficient transgenic mice. Endocrinology (1990) 127(3):1033–40. doi:10.1210/endo-127-3-1033

312. Rosen T, Hansson T, Granhed H, Szucs J, Bengtsson BA. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) (1993) 129(3):201–6.

313. Saggese G, Baroncelli GI, Bertelloni S, Cinquanta L, Di Nero G. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. J Pediatr (1993) 122(1):37–45. doi:10.1016/S0022-3476(05)83484-5

314. Chandrashekar V, Bartke A, Coschigano KT, Kopchick JJ. Pituitary and testicular function in growth hormone receptor gene knockout mice. Endocrinology (1999) 140(3):1082–8. doi:10.1210/endo.140.3.6557

315. Dominici FP, Arostegui Diaz G, Bartke A, Kopchick JJ, Turyn D. Compensatory alterations of insulin signal transduction in liver of growth hormone receptor knockout mice. J Endocrinol (2000) 166(3):579–90. doi:10.1677/joe.0.1660579

316. Keene DE, Suescun MO, Bostwick MG, Chandrashekar V, Bartke A, Kopchick JJ. Puberty is delayed in male growth hormone receptor gene-disrupted mice. J Biol Chem (2002) 277(5):661–8.

317. Berryman DE, List EO, Coschigano KT, Behar K, Kim JK, Kopchick JJ. Comparing adiposity profiles in three mouse models with altered GH signaling. Growth Horm IGF Res (2004) 14(4):309–18. doi:10.1016/j.ghir.2004.02.005

318. Egecioglu E, Bjursell M, Ljungberg A, Dickson SL, Kopchick JJ, Bergstrom G. Growth hormone receptor deficiency results in blunted ghrelin feeding response, obesity, and hypolipidemia in mice. Am J Physiol Endocrinol Metab (2006) 290(2):E317–25. doi:10.1152/ajpendo.00181.2005

319. Izzard AS, Emerson M,Prehar S, Neyses L, Trainer P, List EO, et al. The cardiovascular phenotype of a mouse model of acromegaly. Growth Horm IGF Res (2009) 19(3):413–9. doi:10.1016/j.gihr.2008.12.006

320. Powell-Braxton L, Hollingshead P, Giltinan D, Pitts-Meek S, Stewart T. Inactivation of the IGF-1 gene in mouse results in perinatal lethality. Ann N Y Acad Sci (1999) 892:300–1. doi:10.1111/j.1749-6632.1999.tb26240.x

321. Woods KA, Camacho-Hubner C, Savage MO, Clark AJ. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med (1996) 335(18):1363–7. doi:10.1056/NEJM1996103333351805

322. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol (2001) 229(1):141–62. doi:10.1006/dbio.2000.9975

323. Nilsson A, Isogard J, Lindahl A, Peterson L, Isaksson O. Effects of unilateral arterial infusion of GH and IGF-I on tibial longitudinal bone growth in hypophysectomized rats. Calcif Tissue Int (2004) 14(4):309–18. doi:10.1016/j.bon.2004.02.005

324. Dobie R, Ahmed SF, Staines KA, Pass C, Jasim S, MacRae VE, et al. Increased linear bone growth by GH in the absence of SOCS2 is independent of IGF-1. J Cell Physiol (2015) 230(11):2796–806. doi:10.1002/jcp.25006

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Dehkhoda, Lee, Medina and Brooks. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.